Literature DB >> 24978327

Incidental diagnosis of diffuse large B-cell lymphoma by 11C-choline PET/CT in a patient with biochemical recurrence of prostate cancer.

Jr Garcia Garzon1, Pere Bassa, Merce Moragas, Marina Soler, Eduard Riera.   

Abstract

The main indication for C-choline PET/CT in prostate cancer patients is the early localization of biochemical recurrence after radical treatment. However, any C-choline uptake should be assessed in terms of physiological distribution and patterns of tumor spread. Therefore, tracer-avid lesions in unexpected sites should be carefully addressed because the diagnosis of other malignancies has important therapeutic implications. We present a patient with biochemical recurrence of prostate cancer treated with radiotherapy. C-choline PET/CT showed local recurrence and inguinal lymph node uptake. Because of its location beyond typically prostatic lymphatic spread, resection was performed. Histology confirmed a diffuse large B-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24978327     DOI: 10.1097/RLU.0000000000000495

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Unusual uptakes on 18F-fluorocholine positron emission tomography/computed tomography (PET/CT): a retrospective study of 368 prostate cancer patients referred for a biochemical recurrence or an initial staging.

Authors:  Antoine Roland; Clément Drouet; Hatem Boulahdour; Alexandre Cochet; Berardino De Bari
Journal:  Quant Imaging Med Surg       Date:  2021-01

2.  Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series.

Authors:  Martina Sollini; Francesco Pasqualetti; Marzio Perri; Gabriele Coraggio; Paolo Castellucci; Massimo Roncali; Roberto Boni; Elena Lazzeri; Maria Galeandro; Fabiola Paiar; Annibale Versari; Paola Anna Erba
Journal:  Cancer Imaging       Date:  2016-08-31       Impact factor: 3.909

Review 3.  ChoK-Full of Potential: Choline Kinase in B Cell and T Cell Malignancies.

Authors:  Samantha Gokhale; Ping Xie
Journal:  Pharmaceutics       Date:  2021-06-20       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.